Surveys into the pharmacological constituents of ecstasy tablets, dosage levels, and empirical reports of their perceived purity, provide the main data for this review.ĭuring the 1980s and early 1990s there were few problems with the purity of ecstasy tablets, and the biochemical evidence shows that they nearly always contained MDMA.

The historical origins and evolution of this mismatch will be reviewed, in order to estimate the proportions of ecstasy tablets containing MDMA at different periods over the past 30 years. Not every tablet sold as 'ecstasy' contains MDMA (3,4-methylenedioxymethamphetamine). Validated and subsequently applied to the analysis of plasma and oral fluid samples collected from current drug users. Limits of detection of 2 µg/L or better were obtained. Of 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, amphetamine, methamphetamine,Īnd ephedrine in a single chromatographic run. Sample, has a total analysis time of less than 20 min (including sample preparation) and enables the simultaneous quantitation The developed method, which requires only 50 µL of biological Of the drugs was performed using multiple reaction monitoring. Precipitation step and subsequently analyzed using reversed-phase liquid chromatography-tandem mass spectrometry. Amphetamines were isolated from human plasma and oral fluid using a simple methanol The development of an alternative method. However, this procedure is labor-intensiveĪnd time-consuming, particularly as a preliminary extraction and derivatization are usually unavoidable. Target analysis of amphetamines in biological samples is of great importance for clinical and forensic toxicologists alike.Īt present, most laboratories analyze such samples by gas chromatography-mass spectrometry.

The method showed a good seletivity as the epinephrine, cocaine, amphetamine, methamphetamine, acethyl salicilic acid, diethyl barbituric acid, p-aminobenzoyl diethyl barbituric, paracetamol and caffeine presences did not interfere with the measurement of the three analytes. The detection limits were 0.7 µg/mL, 0.8µg/mL and 0.6µg/mL respectively to MDMA, MDA and MDEA. The analytic validation results for MDMA, MDA and MDEA were linearity range of 1.0 to 500.0 µg/mL, intra and interassay coefficient of variation lower than 9.5% and quantification limit of 1.0 µg/mL. It was chosen for development and validation a gas chromatography method with flame ionization detection. The present study sought to develop and validate an analytical method for determination of MDMA, MDA and MDEA in tablets to be accessible for the most small or medium laboratories of toxicology of the development countries as Brazil. Many tablets samples kept on the streets shown the presence not only of the MDMA- 3,4-methylenedioxymethamphetamine, the main drug component but also of the MDA 3,4- methylenedioxyamphetamine and MDEA - 3,4-methylenedioxymethylethylamphetamine. The abusive use of the amphetamine derivative ecsyasy in the world come increasing in the last years.

Developer amphetamine